Roivant Sciences Ltd. (ROIV): M&A transaction — Roivant closes $7.1B sale of Telavant to Roche; retains 75% ownership prior to closing

Roivant Sciences Ltd.

Total upfront cash consideration of approximately $7.1 billion paid to Telavant equity holders.
Roivant owned 75% of Telavant on an as-converted basis before the transaction closed.
Additional $150 million cash milestone payable upon initiation of a Phase 3 ulcerative colitis trial.
Telavant holds US and Japan rights to TL1A antibody RVT-3101 for IBD and Crohn's disease.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Roivant Sciences Ltd. completed a disposition involving Roche Holdings, Inc. for approximately $7.1 billion in cash (closed 2023-12-14).

Action: disposition
Counterparty: Roche Holdings, Inc.
Consideration: approximately $7.1 billion in cash
Closing: 2023-12-14

Exact text from the filing

On December 14, 2023, pursuant to the Purchase Agreement, the Buyer completed the Transaction for total consideration of approximately $7.1 billion in cash at the closing of the Transaction (the “Closing”), paid or to be paid to all of Telavant’s equity holders, including holders of restricted stock units, on a pro rata basis relative to their ownership of Telavant prior to the Closing.

View on SEC.gov

24 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-057578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.